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sulfate (100%), Magnesium sulfate (100%) and Ondansetron (70%). In our study total 
cost of drugs (300974.4 rupees), in total cost Ondansetron has 14.7% and least was 
amlodipine of 0.018%. CONCLUSIONS: There are 32 adjunctive drugs used in inpa-
tient oncology department. The drug utilization study we conducted helped to know 
the prescribing and usage pattern of drugs in inpatient radiotherapy department, 
there by the indenting of drugs is very easy without any drug lackage. The cost 
considerations are helped for proper budget preparation.
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OBJECTIVES: Treatment for resected melanoma at high risk for progression has 
generally consisted of adjuvant interferon alfa-2b, the only adjuvant melanoma 
therapy approved in the US. This study sought to describe patterns of systemic adju-
vant therapy, clinical outcomes, and healthcare costs among melanoma patients 
treated in the US community oncology setting. METHODS: This was a retrospective 
observational study of adult patients with Stage I-III melanoma identified between 
1/1/2007 and 4/1/2013 in the Vector Oncology Data Warehouse. Descriptive statistics 
were used to describe patient demographic and clinical characteristics for those 
treated and untreated with systemic adjuvant therapy. Only patients who received 
interferon/peginterferon as their adjuvant systemic therapy were evaluated for 
treatment patterns and clinical outcomes including time to treatment initiation 
and disease-free survival (DFS). Total direct healthcare cost and costs associated 
with systemic therapy were calculated per patient per month (PPPM) based on 
imputation from billing record charges and utilization history. RESULTS: Of the 
636 patients identified, 149 (23.4%) were treated with adjuvant systemic therapy. 
Of these, 137 received interferon/peginterferon therapy. Median time from surgical 
resection to start of interferon/peginterferon was 2.6 months and median duration 
of therapy for patients treated with interferon was 3.5 months. Approximately, 75% 
of patients remained on therapy at one month and by one year, only 25% of the 
patients remained. Median DFS was a little more than three years (38.2 months). 
Median (IQR) total cost associated with first-line systemic therapy was $18,154 
($10,139, $38,477) PPPM; $13,416 ($8,190, $28,725) of that cost was attributable to 
interferon/peginterferon therapy (2014 dollars). CONCLUSIONS: This study suggests 
that in this community oncology setting, adjuvant melanoma treatment comprised 
mostly interferon/peginterferon therapy. Only 25% of patients received the full rec-
ommended 1-year course of interferon therapy. These results highlight the need for 
better and more tolerable treatments in the adjuvant setting.
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OBJECTIVES: Across geographies, governments and institutions are implementing 
additional administrative burdens on clinicians while prescribing high cost oncology 
products. In an effort to reduce prescriptions and control healthcare expenditure, 
these restrictions have been put in place as a means of prescription justification and 
to ensure careful thought has been invested into each patient. This research sought 
to investigate the prevalence, impact and outcomes of such schemes. METHODS: 
The research was conducted through in-depth interviews with payers and clinicians 
across 10 EMEA markets. RESULTS: In many markets studied, there are systems 
currently in place to ensure appropriate prescription of high cost products. These 
additional requirements may be manifested in supplemental forms that must be 
filled out by the prescribing clinician (e.g. Norway), online patient registrations 
and database entry (e.g. Italy), additional pharmacist justification (Saudi Arabia) 
or additional physician justification (e.g. Slovakia). CONCLUSIONS: Payers viewed 
some protocols as being more effective than others to combat adverse prescrip-
tion, while clinicians viewed them as being time consuming and often annoying. 
Interestingly, physicians found loop-holes as a way to avoid the additional burden 
and time required to prescribe high cost oncology products. Physicians were not 
concerned with these systems permanently restricting access of high cost products 
to their patients. However, their main concern was that these additional procedures 
are causing delays in the initiation of treatment and require additional effort.
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OBJECTIVES: The Cancer Care Quality Program (CCQP), a novel program by Anthem 
Inc. health plans designed to align reimbursement with evidence-based, cost-effec-
tive oncology treatment, collects clinical data that can be integrated with the admin-
istrative claims data in the HealthCore Integrated Research Database (HIRD). This 
study evaluated baseline characteristics of patients within oncology practices par-
ticipating in the CCQP. METHODS: Breast, colon, and lung cancer patients from prac-
tice sites participating in the CCQP were identified between 6/23/2014 and 12/3/2014 
(Intake Period). Patients were characterized based on the earliest request to utilize 
chemotherapy and/or supportive care medications (Index Date) during the Intake 
Period; analyses included patients with ≥ 6 months of continuous pre-index eligibil-
ity. CCQP clinical data was integrated with HIRD administrative claims data. Baseline 
characteristics were stratified by cancer type/stage and included: pathology, bio-
markers, ECOG performance status, and Deyo-Charlson Index (DCI). RESULTS: A 
total of 1,230 breast, 329 colon, and 554 lung cancer patients were identified with 
mean(SD) ages and DCI’s of 55(11), 58(10), and 62(9) and 5.7(3.2), 7.6(2.6), and 7.7(2.8), 
at a provincial level may be required to offset the inherent uncertainty in the 
resulting ICER estimation.
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OBJECTIVES: The Appalachia region experiences excess cancer mortality and a lack 
of access to cancer care resources. There is limited research examining adjuvant 
treatment use disparities in this region. This study aims to explore adjuvant endo-
crine therapy (AET) utilization in Appalachia, and delineate the effects of access 
to cancer on AET use. METHODS: We linked female breast cancer patients identi-
fied in cancer registries from the Appalachian counties in four states (KY, NC, OH, 
PA) to 2006-2008 Medicare claims data. We included patients with invasive, non-
metastatic, hormone-receptor-positive breast cancer and assessed the prevalence 
of receiving guideline-recommended AET. We then assessed AET adherence among 
those who received guideline-recommended AET using the Medication Possession 
Ratio (MPR), and determined non-persistence, defined as exceeding a 60-day medi-
cation gap. We also used survival analyses to examine the influences of adherence 
and persistence on overall survival. RESULTS: Only 450 of the 946 eligible patients 
(47.6%) received guideline-recommended AET, which was significantly associated 
with shorter travel time to receive care, dual Medicare and Medicaid eligibility, being 
unmarried (vs. married), and living in Pennsylvania (vs. Ohio). The non-adherence 
rate was about 31% and non-persistence rate was 30% over an average follow-up 
period of 421 days. Tamoxifen, relative to aromatases, was associated with higher 
odds of adherence (OR = 2.82, p < 0.001) and a lower risk of non-persistence (HR = 
0.40, p < 0.001). Side effects like pain may be an important factor leading to non-
adherence and early discontinuation. Non-adherence to and non-persistence with 
AET were associated with higher risks of all-cause mortality. CONCLUSIONS: In 
Appalachia, geographic and socioeconomic factors such as travel time to receive 
care and healthcare plan type are important elements that could contribute to 
disparities in access to adjuvant treatment, while treatment choice and medication-
related factors may exert strong influences on AET use behaviors.
PCN148
geNder-sPeCIfIC dIffereNCes IN rIsk for Cost-relAted MedICAtIoN 
NoNAdhereNCe AMoNg CANCer sUrvIvors
Lee M.J., Li Y., Khan M.M.
University of South Carolina, Columbia, SC, USA
OBJECTIVES: Cancer survivors have been reported delaying or avoiding care due 
to costs. Cost-related medication nonadherence (CRN) is associated with worse 
health outcomes, including stroke, heart disease, and hospitalizations. This study 
was conducted to estimate the prevalence and factors of CRN among cancer sur-
vivors. METHODS: Using the 2013 Behavioral Risk Factor Surveillance System 
(BRFSS), we will examine self-reported CRN among cancer survivors. In total, 
491,773 subjects, including 44,968 (0.09%) cancer survivors, who reported CRN 
in the past 12 months were identified. Descriptive statistics and multiple logis-
tic regression models were used to characterize and to identify factors affecting 
CRN among cancer survivors. RESULTS: In a nationally representative sample 
of 44,968 cancer survivors, 3,328 (7.4%) were CRN-reported (851 men and 2,477 
women). Cancer survivors who reported CRN (n= 3,328) were younger, live in the 
South, more likely to be less educated, more likely to be female and Hispanic, 
and more likely to have health care coverage, lower household income, multiple 
comorbidities, poorer self-rated health status, and activity limitation. In adjusted 
analyses, men with younger age, black or Hispanic race, lower household income, 
no health care coverage, health care coverage, multiple comorbidities, poorer self-
rated health, and activity limitation were significantly more likely to report CRN. 
Women with younger age, Hispanic or other race, South living, lower household 
income, higher education, no health care coverage, health care coverage, multiple 
comorbidities, poorer self-rated health, and activity limitation were significantly 
more likely to report CRN. CONCLUSIONS: Significant gender-specific differences 
were found among factors related to CRN among cancer survivors. Given the high 
cost sharing under drug coverage, it is important to closely monitor CRN in high-
risk subgroups. Further studies are warranted to establish effective interventions 
in this vulnerable population.
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OBJECTIVES: The objective of adjunctive drug utilization pattern is to know the 
proportion of adjunctive drugs used in cancer inpatient’s , to improve the quality of 
health care, for proper planning of indenting and budgeting of adjunctive drugs in 
Oncology (Radiotherapy) Department. METHODS: The study was conducted in the 
Oncology (Radiotherapy) Department of Guntur Medical College and Government 
General Hospital, Guntur. The study method includes prioritizing the patients based 
on inclusion and exclusion criteria. Information regarding drug utilization is col-
lected with the aid of a data collection form from the inpatient’s case sheets. The col-
lected data will be tabulated and analyzed using suitable statistical tools. RESULTS: 
The most commonly observed cancer type was cervix ( 26.54%) followed by Head 
and Neck ( 23.9%). In our study, we observed that there is more prevlence(80%) of 
gynaecological cancers in women. There was female predominance (67%) in cancer 
prevalence. The present study shows maximum number of patients are between 
the age group of 40- 60 years (33.6%). The total drugs used in inpatient oncology 
department are 70450, among all the drugs 16015 are parenteral formulations, 
whereas 54435 are oral formulations. Ondansetron is the mostly used drug (17.5%) 
followed by diclofenac (12.7%) and ranitidine (12.5%). The drugs use for prevention 
of chemotherapy induced adverse drug reactions include mesna (100%), Potassium 
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were extracted alongside whether the priority status, pre- or post-NOC pCODR 
submission, and if the drug was a first submission or line extension. Statistical 
comparisons were made using Student’s t-test. RESULTS: 32 pCODR reports were 
extracted with an average of 203 days between pCODR submission to recom-
mendation, with a wide variation between different drugs (range: 119-329 days, 
median: 198). There was no significant variation in the average time required 
for pCODR decision-making based on priority status (prioritisation granted: 232 
days, [n= 3]; prioritisation not granted: 202 days, [n= 29]; p= 0.17). There was also no 
significant variation in time required for line extensions versus first submissions 
(line extension: 197 days, [n= 9]; first submissions: 205 days, [n= 23]; p= 0.34). pCODR 
decision-making time did also not significantly vary between those submitted 
prior- versus post-regulatory approval (pre-NOC: 213 days, [n= 18]; post-NOC: 191 
days, [n= 14]; p= 0.26). CONCLUSIONS: Although there are some wide variations 
in the time required for pCODR to issue recommendations between different 
drugs, this did not correlate with prioritisation status, whether the drug was a 
first submission or line extension, or if a submission was made pre-or post-NOC 
in a statistically significant manner. However, the small sample sizes may have 
precluded finding statistical significances. Further research is needed to define 
the key factors underlying this variation.
PCN157
IMPACt of federAl regUlAtIoN oN ACCess to orAl CheMotherAPy (oC) 
ANd horMoNAl therAPy (ht) IN the BrAzIlIAN PrIvAte heAlth systeM 
(Phs)
Piedade A.1, Castro A.P.2, Alves A.F.1, Nishikawa A.M.1, Minowa E.1
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências, Campinas, Brazil
OBJECTIVES: Recently, the use of OC and HT either as monotherapy, or added to/
replacing intravenous chemotherapy (CT) drugs for the treatment of different malig-
nancies have increased in Brazil. Federal law number 12880/2013 was one of the 
hallmarks of oncologic drug access as it established the patients’ right to OC coverage 
in the Brazilian Private Healthcare System (PHS), whereas before only the payment 
of intravenous drugs was covered. The aim of this study is to evaluate real-world 
data on OC access one year after the publication of law 12880/2013. METHODS: All 
chemotherapy requests submitted between January 2013 and December 2014, regard-
less of cancer type, were extracted from Evidencias - Kantar Health private market 
administrative claims database. Subsequently, we evaluated all OC/HT requests and 
classified them as approved or denied for coverage, depending on the appropriateness 
of drug indication. The approved ones were assessed and compared monthly and 
yearly in order to evaluate the difference of utilization before and after the publication 
of law 12880/2013. RESULTS: A total of 17,512 requests were individually evaluated. 
There were 2,504 OC and HT (2,228 approved, 276 unapproved) requests. Before law 
12880/2013 was implemented (in January 1st 2014), the total number of requests 
for OC and HT were 332 and 78, respectively. After the mandatory coverage of these 
therapies, there were 622 OC and 968 HT requests (an increase of 87.3% and 1,141%, 
respectively). CONCLUSIONS: A significant increase was observed in the number 
of requests for hormonal therapies such as tamoxifen and anastrozole in 2014. The 
increase in number of hormonal therapy requests was more marked then that of OC.
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OBJECTIVES: Evidenced-based guidelines for the treatment of breast cancer have been 
put forth by agencies such as the National Comprehensive Cancer Network (NCCN). 
Yet, even with specific guidelines, gaps in the receipt of appropriate care exist. This 
study examined factors associated with receipt of appropriate vs. inappropriate treat-
ment among elderly women with breast cancer in the U.S. METHODS: A sample of 
11,948 women age > 66 with pathologically staged I, II, and III breast cancer diagnosed 
from 2004 to 2006 were selected from the SEER-Medicare linked dataset. Algorithms 
based on clinical cancer characteristics and types of treatments and testing received 
were used to determine appropriateness of care (yes vs. no). Logistic regression 
models were used to examine the relationship between appropriateness of care and 
various independent factors. RESULTS: Less than 32% of elderly women received 
guideline appropriate care. The likelihood of receiving appropriate care decreased for 
women with increasing age (> 80 vs. 66-69) (AOR, 0.23; 95%CI, 0.20-0.27), comorbidity 
(> 2 vs. 0) (AOR, 0.85; 95%CI, 0.75-0.97), stage (III vs. I) (AOR, 0.50; 95%CI, 0.40-0.61) and 
(II vs. I) (AOR, 0.33; 95%CI, 0.28-0.38), and were of non-white race vs. white (AOR, 0.83; 
95%CI, 0.73-0.96). Women with node negative cancer, poorly differentiated tumors, 
borderline/unknown tumor receptors were also less likely to receive appropriate care. 
Yet, the likelihood of appropriate care was increased for women who saw both a gen-
eral and oncology surgeon vs. general surgeon only (AOR, 1.35; 95%CI, 1.19-1.53), lived 
in areas of higher income vs. lower (AOR, 1.15; 95%CI, 1.01-1.30), and higher education 
vs. lower (AOR, 1.15; 95%CI, 1.03-1.29). CONCLUSIONS: Irrespective of guidelines, less 
complex patients with greater resources are more likely to receive appropriate care. 
Better efforts should be made for all elderly women with breast cancer to receive 
appropriate care regardless of their age, health, or resources.
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OBJECTIVES: Many elderly women with early-stage breast cancer (BC) receive mastec-
tomy when breast-conserving surgery (BCS) plus radiation therapy (RT) is an option, 
or do not receive recommended RT following BCS. This study examined associations 
with primary treatment (BCS+RT, mastectomy, or BCS without RT) for early-stage BC 
among elderly women. METHODS: A sample of 26,106 women age > 66 diagnosed 
respectively. Stage distributions indicated the greatest prevalence with stage IV dis-
ease: 39%, 73%, and 68% among breast, colon, and lung cancers patients. Pathology 
results among lung cancer patients demonstrated 78% and 22% with non-small 
cell and small cell cancers, respectively. 36% of breast cancer patients were HER2 
positive, 29% of lung cancer patients were detected with EGFR mutation, and 39% of 
colon cancer patients were detected with KRAS mutation among those reporting test 
results. The majority of patients in each cancer group (81.7%-90.3%) had an ECOG 
performance status of 0 or 1. CONCLUSIONS: Given the recent implementation of 
the CCQP, this analysis provides valuable initial insight into the demographic and 
clinical characteristics of patients within participating practices. This integrated 
data provides a comprehensive picture for commercially-insured oncology patients 
and baseline data for future program evaluation.
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OBJECTIVES: Medicare contracting reform resulted in the replacement of Medicare 
Part A/B claims processors, known as fiscal intermediaries (FIs) and carriers, with 
Medicare Administrative Contractors (MACs). This study examines the implemen-
tation of MACs on the receipt of chemotherapy and biologic agents for the treat-
ment of metastatic colon cancer (mCC). METHODS: This retrospective study used 
Surveillance, Epidemiology and End Results (SEER) Medicare data to examine the 
receipt of National Comprehensive Cancer Network (NCCN) approved chemotherapy 
and biologic agents by elderly patients with mCC who were diagnosed between 2006 
and 2009 and followed through 2011. The odds ratios associated with the interac-
tion between pre/post MAC implementation and whether the implemented MAC 
had previously been a FI/carrier in the region were estimated using a generalized 
linear mixed model with a random effect for SEER-region. Age, race, marital status, 
gender, Medicaid buy-in, poor-performance status, the Charlson Comorbidity Index 
and year of diagnosis were covariates in the model. RESULTS: The final sample 
included 9,509 patients. 4,034 (41%) received NCCN-approved chemotherapy at any 
time after diagnosis and 2202 (22%) received an NCCN-approved biologic at any time 
after diagnosis. Individuals diagnosed post-implementation in a region where the 
MAC was not previously a FI/carrier had no reduction in the odds of receiving either 
NCCN-approved chemotherapy (odds ratio [OR]: 0.95, 95% confidence interval [CI]: 
0.69–1.29) or NCCN-approved biologics (OR: 1.17, 95% CI: 0.85–1.61) at any time after 
cancer diagnosis as compared with patients diagnosed in the post period where the 
MAC was previously a FI/carrier. CONCLUSIONS: Evidence was not found to support 
the hypothesis that MAC implementation impacted the odds of a Medicare mCC 
patient receiving NCCN-approved chemotherapy or biologic agents. Future research 
should focus on examining the impact of Medicare contracting reform on specific 
treatment lines in combination with biologic use.
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OBJECTIVES: The main objective of this study is to identify the sequences followed 
and delays encountered by each anticancer product between the country of origin 
and the delivery point at the main anti-cancer center in Algeria the CPMC. A second 
objective is to evaluate the effects of the introduction of the special procedure called 
“temporary authorization of a use” (TAU). METHODS: A sample of Oncology drugs 
was determined for the period 1999–2013. These oncology products were approved 
by the European medicines agency. A sample of 60 products was selected. The main 
sequences studied were: Date of market authorization by EMA and Algeria, date of 
first purchase by the central pharmacy for hospitals (responsible for procurement of 
inpatients drugs) and date of registration of the drug on the list of oncology products 
used by the CPMC. The sequences and time periods have been identified but also 
analyzed using a regression model. RESULTS: The analysis shows that 30% drugs 
have been registered in Algeria and the overall mean time required before patients 
access was 32 months: Between 1999-2007 (pre-ATU) it was 48 months and 25 month 
for 2007-2012 (post- ATU). The high product prices have been felt as a serious obstacle 
to large introduction and access, moreover we identified a significant differences 
in term of the early access between the companies implemented in the local mar-
ket and the companies who set up a liaison offices in Algeria. CONCLUSIONS: This 
study identified some of the main factors affecting the introduction and diffusion of 
oncology drugs from between the European market and the main delivery point to 
patients in Algeria. Strengthening national capacities and mechanisms to evaluate 
real performance and cost-effectiveness should be more than ever on the agenda 
of the national health authorities as oncology drugs is representing almost half of 
budget for pharmaceuticals.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established 
in 2010 to appraise oncologics to help guide provincial decision-making. pCODR 
prioritises reviews for new drugs that offer potential substantial improvements 
on significant outcomes and will also accept submissions prior to a Notification 
of Compliance (NOC) of regulatory approval being granted. This research aims to 
define the time required for pCODR to issue recommendations and what factors 
affect the decision-making time. METHODS: All published pCODR reports were 
extracted up to 30 September 2014 and the dates of submission and notification 
